InvestSMART

MedAdvisor Limited (ASX:MDR)

ALERT: Price-sensitive ASX Announcement for MDR
Current share price for MDR : $0.022 -0.006 (-21.43%)+
Announcement
Release
22 Oct 2025 9:52AM
Price at Release
$0.028
Full Release
download
Summary
The 1Q FY26 Investor Presentation for MedAdvisor Limited highlights a challenging period, with a notable 52.8% decrease in revenue attributed to regulatory delays impacting vaccine programs and financial difficulties in the pharmacy sector. The gross profit also saw a substantial decline, alongside a decrease in gross margin. As part of strategic transformation efforts, the company is launching a new patient engagement system in the next quarter and has sold its ANZ business for $35 million. MedAdvisor is focusing on unlocking shareholder value through a strategic review and is exploring AI solutions to enhance its competitive edge. Despite current challenges, the company enters FY26 with a robust US$100 million pipeline and plans to restart several general medication programs in the second quarter.
Key Points
  • MedAdvisor experienced a significant 52.8% decline in revenue in 1Q FY26 compared to the previous year.
  • Revenue was impacted primarily by regulatory delays affecting vaccine programs and financial challenges in the pharmacy sector.
  • Gross profit fell by 60.4% with the gross margin decreasing by 8.1 percentage points.
  • The company is focused on business transformation, including launching a new patient engagement system in 2Q FY26.
  • MedAdvisor has sold its ANZ business to Jonas Software AUS Pty Ltd for $35 million.
  • Strategic options are being evaluated to unlock shareholder value and address a valuation disconnect.
  • The company plans to accelerate AI solutions to enhance competitive differentiation and customer value.
  • MedAdvisor's strong US$100 million pipeline for FY26 includes restarting general medication programs in 2Q FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.